Linfoma de Burkitt en pacientes HIV positivo tratados con quimioterapia intensiva en el Hospital del Salvador entre 2011 y 2014: Protocolo Nacional de Cáncer del Adulto, Chile / Intensive chemotherapy for Burkitt lymphoma in HIV positive patients
Rev. méd. Chile
; 143(12): 1505-1511, dic. 2015. graf, tab
Article
in Es
| LILACS
| ID: lil-774434
Responsible library:
CL1.1
ABSTRACT
Background:
Burkitt lymphoma has a low incidence, is highly aggressive, may be endemic, sporadic or associated with immunodeficiency and it has a high frequency of extranodal involvement. Overall and relapse free survival in HIV patients is 72 and 71% respectively. However, the current protocol in Chile considers a positive HIV serology as an exclusion criterion for intensive chemotherapy.Aim:
To analyze the response to Burkitt lymphoma treatment among HIV positive patients. Material andMethods:
All HIV positive patients with a Burkitt lymphoma treated using PANDA protocol in a public hospital were analyzed.Results:
Eight male patients aged between 25 and 43 years, 63% in stage IV, were analyzed. All patients received an intensified chemotherapy regime, three of them without Rituximab. Complete remission was achieved in 87%. One patient was refractory to treatment and one patient relapsed at 5 months and died. Overall and relapse free survival were 58 and 60% respectively. All patients had episodes of high risk febrile neutropenia, but it did not cause deaths.Conclusions:
In this group of HIV patients, intensive chemotherapy for Burkitt lymphoma had a high degree of effectiveness with a low relapse rate and high cure rate.Key words
Full text:
1
Index:
LILACS
Main subject:
Fractures, Bone
/
Sarcopenia
Type of study:
Guideline
Limits:
Humans
Country/Region as subject:
America central
/
America do sul
/
Chile
/
El salvador
Language:
Es
Journal:
Rev. méd. Chile
Journal subject:
MEDICINA
Year:
2015
Type:
Article